SUBSCRIBE
SUBSCRIBE
Kate Goodwin

Kate Goodwin

Contributing Writer | News & Features

Kate Goodwin hails from a background primarily in marketing. A passion for health sciences and writing led her to the biopharma news world, and she’s never looked back. She’s been writing for BioSpace for more than two years with a focus on cutting edge research, Alzheimer’s disease and pediatrics. Her free time is filled by her husband, children, Beagles, books, crochet and creative writing. She can be reached at kate.goodwin@biospace.com.

BioMidwest
Newsweek’s Most Responsible Companies are BioSpace’s Best Places to Work
BioSpace compared the 43 healthcare and life science companies on Newsweek’s list of America’s Most Responsible Companies for 2022 with that of our own 2022 Best Places to Work.
February 18, 2022
 · 
4 min read
 · 
Kate Goodwin
Business
Money on the Move: February 9 – 15
As the market seems to be taking a turn against biotech stock, more companies are opting for private funding instead of going public for the moment. And VC firms are happy to jump in.
February 15, 2022
 · 
3 min read
 · 
Kate Goodwin
Drug Development
Proactive > Reactive: Science Targets Universal Coronavirus Vaccine
While the “speed of science” to develop a successful coronavirus vaccine against the novel COVID-19 has been record-setting, scientists are telling us it’s not enough.
February 15, 2022
 · 
3 min read
 · 
Kate Goodwin
Business
East Coast Pain Player Expands Portfolio with $604M Buyout
Stoughton, Mass.-based Collegium Pharmaceutical is expanding its pain-treating portfolio with a $604 million buyout of Raleigh’s BioDelivery Sciences International (BDSI).
February 14, 2022
 · 
2 min read
 · 
Kate Goodwin
Drug Development
Study: COVID-19 Infection Can Attack Placenta, Increasing Risk of Stillbirth
New research published this week gives a greater understanding of why the CDC warned of an increased risk of stillbirth for women infected by SARS-CoV-2 during pregnancy in November.
February 11, 2022
 · 
3 min read
 · 
Kate Goodwin
Business
Bayer Takes a Leap for Off-the-Shelf NK Cell Therapy
Bayer joined in the $50 million Series A for San Francisco’s Indapta Therapeutics.
February 10, 2022
 · 
2 min read
 · 
Kate Goodwin
Nicola Gell/Getty Images for SXSW
Business
CRISPR Pioneer Doudna Joins Global Investment Firm as CSO
Jennifer Doudna will act as Chief Science Advisor to build a Scientific Advisory Board for Sixth Street, advising the investment firm on CRISPR-related opportunities.
February 8, 2022
 · 
2 min read
 · 
Kate Goodwin
Frank Crymble, Getty Images
Business
Vancouver Startup Nets $40M to Marry the Power of Cryo-EM and AI
The union has one primary goal – speed up discovery and development to get effective drugs to patients sooner.
January 31, 2022
 · 
2 min read
 · 
Kate Goodwin
Business
Oxford Biomedica and Homology Medicines Strike a Win-Win Deal
Oxford BioMedica and Homology Medicines have formed a symbiotic partnership to launch a full scope AAV manufacturing and innovation business.
January 28, 2022
 · 
3 min read
 · 
Kate Goodwin
Policy
Report Shows Americans Pay More for Drugs Than the Countries Making Them
Americans pay the highest drug prices in the world while importing drugs for lower prices from other countries has been locked down on a personal level and labeled as “unsafe.”
January 27, 2022
 · 
4 min read
 · 
Kate Goodwin
Biotech Bay
Money on the Move: January 19 – 25
Temps are falling and so is investor cash. Here’s which biotech companies are scooping up the dollars this week.
January 25, 2022
 · 
4 min read
 · 
Kate Goodwin
Drug Development
Pandemic Health Systems Reimagined in Supermind Report
The expert group referred to as “Supermind” shared ideas on five areas over four-weeks last year. Here are some of the highlights.
January 25, 2022
 · 
4 min read
 · 
Kate Goodwin
Yichuan Cao/NurPhoto via Getty Images
Drug Development
Elon Musk’s Brain Implants Move Toward In-Human Trials
Visionary tech magnate Elon Musk is taking his neurotech company to the next step toward in-human trials of his implantable brain-machine interface.
January 21, 2022
 · 
2 min read
 · 
Kate Goodwin
BioForest
Drug-Resistant Bacterium Second Only to COVID-19 for Leading Cause of Death by Infection
Infections caused by drug-resistant bacteria kill nearly as many people worldwide as HIV and malaria combined.
January 20, 2022
 · 
3 min read
 · 
Kate Goodwin
Deals
Money on the Move: January 12 – 18
Funds are always flowing in the life science industry. Here’s where the money’s headed this week.
January 18, 2022
 · 
2 min read
 · 
Kate Goodwin
Load More